MRI scans or fewer CT scans can be safely used to monitor for recurrence in people who have undergone surgery for early-stage testicular cancer, according to results from a large clinical trial.
The Food and Drug Administration (FDA) has approved a combination of two immunotherapy drugs for the treatment of some people with advanced melanoma. The drugs, nivolumab and relatlimab (sold together as Opdualag), target the immune checkpoint proteins PD-1 and LAG-3. Results from a large clinical trial called RELATIVITY-047 supported the approval.
Clinical Trials Information for Patients and Caregivers
Although the experimental treatment given in clinical trials is typically free, people who take part are often required to pay costs associated with usual care. This page discusses what costs health insurance plans are required to cover in clinical trials, what conditions must be met for insurance to cover these costs, and what costs plans do not cover.
In this phase 1 trial, people with peritoneal carcinomatosis will be assigned by chance to one of four heated intraperitoneal chemotherapy (HIPEC) treatments given during surgery. Using an experimental lab test, researchers will compare tumor tissue removed during surgery and then treated with HIPEC in the lab with tissue removed after HIPEC treatment in the operating room. Researchers want to see if the lab test accurately shows how HIPEC affects the cancer in the tissue removed during surgery.
This clinical trial will compare two surgical procedures to see how well they work in reducing the risk of ovarian cancer in people at high risk because of a genetic mutation. People with mutations in their BRCA1gene will undergo surgery to either remove both their ovaries and fallopian tubes or just their fallopian tubes. Doctors want to see if removing only the fallopian tubes will be as effective at preventing ovarian cancer while preserving some ovarian function.
This phase 2 trial will test the targeted drug cabozantinib (Cabometyx/Cometriq) added to the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with advanced or metastatic rare cancers of the genitourinary tract (reproductive and urinary organs). Doctors will examine whether there is a measurable response to the combination therapy for each type of cancer studied. They will also assess overall survival, progression-free survival, and the safety of the regimen.
